

06-06-05

TR 632



Express Mail Mailing Label No. EL984318974US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Alexander Rossi Docket No.: 28020/US
Serial No.: 10/053,355 Group Art Unit: 1632
Filed: November 8, 2001 Examiner: Janice Q. Li
For: **PRODUCTION OF CULTURED HUMAN MAST CELLS AND
BASOPHILS FOR HIGH THROUGHPUT SMALL MOLECULE
DRUG DISCOVERY**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL


Enclosed herewith for filing in the above-identified patent application:

- Combined Revocation and Power of Attorney and Statement under 37 CFR 3.73(b);
- Change of Attorney Docket Number; and
- Postcard for date-stamped return as confirmation of receipt of these items.

The Commissioner is further authorized to charge any required additional fees, or credit any overpayment, to Deposit Account Number 50-2778.

Dated: June 2, 2005

Respectfully submitted,


Ann M. Caviani Pease
Reg. No. 42,067

DECHERT LLP
Customer No. 37509
P.O. Box 10004
Palo Alto, CA 94303-0961
Tel. 650.813.4800
Fax. 650.813.4848



Express Mail Mailing Label No. EL984318974US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicants: Alexander Rossi Docket No.: 28020/US
Serial No.: 10/053,355 Group Art Unit: 1632
Filed: November 8, 2001 Examiner: Janice Q. Li
For: **PRODUCTION OF CULTURED HUMAN MAST CELLS AND
BASOPHILS FOR HIGH THROUGHPUT SMALL MOLECULE DRUG
DISCOVERY**

Mail Stop Fee Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CHANGE OF ATTORNEY DOCKET NUMBER

The attorney docket number for this application was formerly entered as 28020/US. It has since been changed to docket number 375462-002US. Please use this new docket number in reference to this application for all future communications.

Respectfully submitted,


Ann M. Caviani Pease
Reg. No. 42,067

Date: June 2, 2005

DECHERT LLP
Customer No. 37509
P.O. Box 10004
Palo Alto, CA 94303
Telephone: 650.813.4800
Facsimile: 650.813.4848



COMBINED REVOCATION AND POWER OF ATTORNEY AND STATEMENT UNDER 37 C.F.R. § 3.73(B)

Rigel Pharmaceuticals, Inc. states that it is the assignee of the entire right, title, and interest to the patent applications/patents identified below by virtue of an assignment from the inventor(s) recorded at the specified reel and frame numbers:

DNW Attorney Docket No.	Dechert Attorney Docket No.	Serial No.	Title	Filed Date	Assignment Recordation
28020/US	375462-002US	10/053,355	Production of Cultured Human Mast Cells and Basophils for High Throughput Small Molecule Drug Discovery	11/8/2001	013020/0239
28715/US	375462-004US	10/098,243	Compounds that Modulate Processes Associated with IGE Production and Methods and Kits for Identifying and Using	3/15/2002	013021/0566
28716/US	375462-005US	10/197,368	Methods of Identifying Compounds that Modulate IL-4 Receptor-Mediated IGE Synthesis Utilizing a CLLD8 Protein	7/16/2002	013390/0522
28718/US	375462-006US	10/197,381	Methods of Identifying Compounds that Modulate IL-4 Receptor-Mediated IGE Synthesis Utilizing an Adenosine	7/16/2002	013393/0869
28717/US	375462-007US	10/197,919	Methods of Identifying Compounds that Modulate IL-4 Receptor-Mediated IGE Synthesis Utilizing a B-Cell Associated Protein	7/16/2002	013387/0320
28721/US	375462-008US	10/197,945	Methods of Identifying Compounds that Modulate IL-4 Receptor-Mediated Synthesis Utilizing a Chloride	7/16/2002	013394/0320



DNW Attorney Docket No.	Bechert Attorney Docket No.	Serial No.	Title	Filed Date	Assignment Recordation
28720/US	375462- 009US	10/197,962	Method of Identifying Compounds that Modulate IL-4 Receptor-Mediated IGE Synthesis Utilizing a Thioredoxin-Like 32 KDA Protein	7/16/2002	013424/0680
28723/US	375462- 010US	10/222,729	Methods of Identifying Compounds that Modulate IL-4 Receptor-mediated IGE Synthesis Utilizing C-MYC Protein	8/16/2002	013565/0845
28575/US/10	375462- 011C1	10/858,343	2, 4-Pyrimidinediamine Compounds and their Uses	6/1/2004	014421/0471
28575/US/11	375462- 011C2	10/911,684	2, 4-Pyrimidinediamine Compounds and their Uses	8/3/2004	014421/0471
28575/US/S	375462- 011US	10/355,543	2, 4-Pyrimidinediamine Compounds and their Uses	1/31/2002	014421/0471
28575/US/US/US	375462- 014US	10/903,263	Methods of Treating or Preventing Autoimmune Diseases with 2, 4-Pyrimidinediamine Compounds	7/30/2004	015598/0939
34674/US	375462- 015US	10/903,870	Methods of Treating or Preventing Autoimmune Diseases with 2, 4-Pyrimidinediamine Compounds	7/30/2004	015598/0954
33502/US/2	375462- 016US	10/931,481	Quinoline Compounds and their Uses	9/1/2004	015611/0890

Assignee hereby revokes all previous powers of attorney and appoints the Dechert LLP attorneys and agents associated with Customer Number 37509 to prosecute the patent applications identified above and to transact all business in the Patent and Trademark Office connected therewith, including full power of association, substitution, and revocation.

Please address all telephone calls and correspondence to Ann M. Caviani Pease at the address corresponding to Customer Number 37509, currently:

DECHERT LLP
1117 California Avenue
Palo Alto, Ca 94304-1106
Tel: (650) 813-4800
Fax: (650) 813-4848

The undersigned (whose title is supplied below) is empowered to sign this statement on behalf of the assignee.

Dated: May 25, 2005

Signature: Dolly Vance

Name: DOLLY VANCE
Title: General Counsel, Vice President of
Intellectual property
Company: RIGEL PHARMACEUTICALS, INC.
1170 Veterans Boulevard
South San Francisco, CA 94080